Erratum: Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341-4351. (Blood (2009) 113(18) (4341–4351), (S0006497120392442), (10.1182/blood-2008-10-186668));CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

Blood

Volumn 113, Issue 18, 2009, Pages 4341-4351

  Azab, Abdel Kareem ^a,b   Runnels, Judith M ^a,b   Pitsillides, Costas ^b   Moreau, Anne Sophie ^a   Azab, Feda ^a   Leleu, Xavier ^a   Jia, Xiaoying ^a   Wright, Renee ^a   Ospina, Beatriz ^a   Carlson, Alicia L ^b   Alt, Clemens ^b   Burwick, Nicholas ^a   Roccaro, Aldo M ^a   Ngo, Hai T ^a   Farag, Mena ^a   Melhem, Molly R ^a   Sacco, Antonio ^a   Munshi, Nikhil C ^a   Hideshima, Teru ^a   Rollins, Barrett J ^a   Anderson, Kenneth C ^a   Kung, Andrew L ^a   Lin, Charles P ^b   Ghobrial, Irene M ^a,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLERIXAFOR; PROTEIN KINASE B; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CXCR4 PROTEIN, HUMAN; FIBRONECTIN; HETEROCYCLIC COMPOUND; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PYRAZINE DERIVATIVE; SMALL INTERFERING RNA; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CELL ADHESION; CELL INTERACTION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; ANIMAL; CELL MOTION; CELL SURVIVAL; CLONOGENIC ASSAY; COCULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; LENTIVIRINAE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; STROMA CELL; TUMOR CELL CULTURE;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; BORONIC ACIDS; CELL ADHESION; CELL MOVEMENT; CELL SURVIVAL; COCULTURE TECHNIQUES; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE, NEOPLASM; FIBRONECTINS; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHA4BETA1; INTERCELLULAR ADHESION MOLECULE-1; LENTIVIRUS; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; PYRAZINES; RECEPTORS, CXCR4; RNA, MESSENGER; RNA, SMALL INTERFERING; STROMAL CELLS; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149150580     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood.2024025275     Document Type: Erratum

References (40)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Richardson PG. A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother. 2004;5:1321-1331. (Pubitemid 38898619)
4. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005;18:619-634. (Pubitemid 40984118)
5. Harousseau JL. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol. 2005;17:93-98.
6. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
7. Ghobrial IM, Leleu X, Hatjiharissi E, et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007;12:155-163.
8. Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028:390-399. (Pubitemid 40361840)
9. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
10. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1:539-544.
11. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38:71-81.
12. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991-6000. (Pubitemid 32955041)
13. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005;18:509-524.
14. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.
15. Akiyama M, Hideshima T, Hayashi T, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002;62:3876-3882.
16. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101:703-705. (Pubitemid 36077596)
17. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106:1901-1910.
18. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109:2708-2717.
19. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879-894. (Pubitemid 41170944)
20. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005;27:1329-1339.
21. Lopez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol. 2004;76:462-471.
22. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003;170:1136-1140.
23. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001;97:346-351. (Pubitemid 32060316)
24. Parmo-Cabanas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixido J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res. 2004;294:571-580.
25. Parmo-Cabanas M, Molina-Ortiz I, Matias-Roman S, et al. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol. 2006;208:108-118.
26. Grignani G, Perissinotto E, Cavalloni G, Carnevale Schianca F, Aglietta M. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. J Clin Oncol. 2005;23:3871-3872; author reply 3872-3873.
27. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110:4417-4426.
28. Shenker BJ HR, Zekavat A, Yamaguchi N, Lally ET, Demuth DR. Induction of apoptosis in human T cells by Actinobacillus actinomycetemcomitans cytolethal distending toxin is a consequence of G2 arrest of the cell cycle. J Immunol. 2001;167(1):435-41.
29. Sotillo R, Dubus P, Martin J, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 2001;20:6637-6647.
30. Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003;63:6689-6696.
31. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221-230.
32. Novak J, Georgakoudi I, Wei X, Prossin A, Lin CP. In vivo flow cytometer for real-time detection and quantification of circulating cells. Opt Lett. 2004;29:77-79.
33. Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969-973.
34. Hideshima T, Chauhan D, Ishitsuka K, et al. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005;24:3121-3129.
35. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
36. Anderson KC, Kyle RA, Dalton WS, et al. Multiple Myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2000:147-165.
37. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
38. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45:295-300.
39. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1095-1102.
40. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867-1874.